Autoimmune diseases induced by biological agents. A double-edged sword?

Autoimmunity Reviews

Volumn 9, Issue 3, 2010, Pages 188-193

  Ramos Casals, Manuel ^a   Roberto Perez Alvarez, ^b   Diaz Lagares, Candido ^a   Cuadrado, Maria Jose ^c   Khamashta, Munther A ^c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL DO MEIXOEIRO   (Spain)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anti TNF therapies; Interstitial lung disease; Lupus; Thrombosis; Vasculitis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; LENERCEPT; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ANTIPHOSPHOLIPID SYNDROME; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CENTRAL NERVOUS SYSTEM; CHOLESTATIC HEPATITIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; DEMYELINATING DISEASE; DERMATOMYOSITIS; DISEASE CLASSIFICATION; DISEASE REGISTRY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EYE DISEASE; GENETIC SUSCEPTIBILITY; GRANULOMATOUS HEPATITIS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LEWIS SUMMER SYNDROME; LUPUS LIKE SYNDROME; MEDLINE; MEMBRANOUS GLOMERULONEPHRITIS; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYOSITIS; NEUROLOGIC DISEASE; NEUROPATHY; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; POLYARTHRITIS; POLYMYOSITIS; POLYNEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THYROIDITIS; TOXIC HEPATITIS; UVEITIS; VASCULITIS;

AUTOIMMUNE DISEASES; EYE DISEASES; HUMANS; LUNG DISEASES, INTERSTITIAL; SPAIN; TUMOR NECROSIS FACTORS;

EID: 72149112759     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.10.003     Document Type: Review

References (38)

1. Ramos-Casals M., Brito-Zerón P., Muñoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86 (2007) 242-251
2. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., and Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43 (2000) 2383-2390
3. Ramos-Casals M., Brito-Zerón P., Muñoz S., Soto M.J., and BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87 (2008) 345-364
4. Ramos-Casals M., Brito-Zerón P., Cuadrado M.J., and Khamashta M.A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 10 (2008) 442-448
5. Ramos-Casals M., Brito-Zerón P., Soto M.J., Cuadrado M.J., and Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22 (2008) 847-861
6. Williams E.L., Gadola S., and Edwards C.J. Anti-TNF-induced lupus. Rheumatology (Oxford) 48 (2009) 716-720
7. De Bandt M., Sibilia J., Le Loët X., Prouzeau S., Fautrel B., Marcelli C., et al., Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7 (2005) R545-R551
8. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Fitzpatrick S.B., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 889-894
9. Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 20 (2008) 35-39
10. Daïen C.I., Monnier A., Claudepierre P., Constantin A., Eschard J.P., Houvenagel E., et al., Club Rhumatismes et Inflammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48 (2009) 883-886
11. Jonsdottir T., Forslid J., van Vollenhoven A., Harju A., Brannemark S., Klareskog L., et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63 (2004) 1075-1078
12. Ferraccioli G., Mecchia F., Di Poi E., and Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 61 (2002) 358-361
13. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 35 (2005) 351-361
14. Sebastian J.K., Voetsch B., Stone J.H., Romay-Penabad Z., Lo G.H., Allen N.B., et al., Wegener's Granulomatosis Etanercept Trial Research Group. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 34 (2007) 2446-2450
15. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47 (1996) 1531-1534
16. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53 (1999) 457-465
17. Stübgen J.P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37 (2008) 281-292
18. Kotyla P.J., Sliwinska-Kotyla B., and Kucharz E.J. Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis. Clin Rheumatol 26 (2007) 1595-1596
19. Shin I.S., Baer A.N., Kwon H.J., Papadopoulos E.J., and Siegel J.N. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 54 (2006) 1429-1434
20. Koike T., Harigai M., Inokuma S., Inoue K., Ishiguro N., Ryu J., et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36 (2009) 898-906
21. Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67 (2008) 189-194
22. Maini R.N., Breedveld F.C., Kalden J.R., et al., Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
23. Braun J., Baraliakos X., Listing J., and Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52 (2005) 2447-2451
24. Sfikakis P.P., Markomichelakis N., Alpsoy E., Assaad-Khalil S., Bodaghi B., Gul A., et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 46 (2007) 736-741
25. Lim L.L., Fraunfelder F.W., and Rosenbaum J.T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56 (2007) 3248-3252
26. Scrivo R., Spadaro A., Spinelli F.R., and Valesini G. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 58 (2008) 1555-1556
27. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves R., Hyrich K.L., et al., British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 68 (2009) 209-215
28. Driessen R.J., Boezeman J.B., van de Kerkhof P.C., and de Jong E.M. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 160 (2009) 670-675
29. Collamer A.N., Guerrero K.T., Henning J.S., and Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 59 (2008) 996-1001
30. González-López M.A., Martínez-Taboada V.M., González-Vela M.C., Fernández-Llaca H., and Val-Bernal J.F. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 158 (2008) 1146-1148
31. Mielke F., Schneider-Obermeyer J., and Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 67 (2008) 1056-1057
32. El Fassi D., Nielsen C.H., Kjeldsen J., Clemmensen O., and Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 57 (2008) 714-715
33. Goetz M., Atreya R., Ghalibafian M., Galle P.R., and Neurath M.F. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 13 (2007) 1365-1368
34. Yazisiz V., Avci A.B., Erbasan F., Yildirim B., and Terzioǧlu E. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 10 (2008) 953-954
35. Song I.H., Appel H., Haibel H., Loddenkemper C., Braun J., Sieper J., et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 35 (2008) 532-536
36. Ahmad K., and Rogers S. Development of Crohn disease in a patient on etanercept for psoriasis. Br J Dermatol 157 (2007) 396
37. Oh J., Arkfeld D.G., and Horwitz D.A. Development of Crohn's disease in a patient taking etanercept. J Rheumatol 32 (2005) 752-753
38. Lee M., Petroniene R., and Thorne C. New onset of inflammatory polyarthritis in a patient taking adalimumab. J Rheumatol 36 (2009) 660